Clal Biotech Selling Diabetes Treatment Co Andromeda

– Clal Biotechnology Industries Ltd. (TASE: CBI) has signed a non-binding letter of intent to sell diabetes treatment developer Andromeda Biotech Ltd. to a US pharmaceutical company for an immediate More...

Teva Sells Andromeda Diabetes Treatment Stake For $72 Million

– Teva will receive $72 million from future sales or from the proceeds of an exit, if any. Diapep277 Slowing the Progression of Type 1 Diabetes. – Clal Biotechnology Industries Ltd. (TASE: CBI) More...

Israeli Weizmann Institute of Science R&D company earns $50-100 million annually

– Products developed by the Weizmann Institute have $20 billion in annual sales. – – / By Gali Weinreb / The campus of the Weizmann Institute of Science gives a sense of abundance to those More...